Hi good morning. My first question is on order book growth. Sudhir, we have seen last few quarters the gap between executable order book growth and the revenue growth has kind of widened. Is it because, the smaller deals which are won and consumed during the years have kind of dried up? And if that is the case, what gives us the confidence that the growth in executable order book would kind of necessarily translate into better revenue growth for us.
Sure, that is helpful. My second question is on testing. I think in our prepared remarks also, we mentioned a lot of GenAI led automation. And we also hear from some of your peers that testing is one area which is ripe for disruption because of GenAI related efficiency gains. Now, in that context, how do we look at Cigniti’s portfolio? Do you think there is a risk because of AI in terms of volume deflation?